Get the Stockscreener App
101.07
2.34%
-2.42
After Hours:
101.25
0.18
+0.18%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $101.07, with a volume of 6.17M.
It is down -2.34% in the last 24 hours and down -13.37% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$103.49
Open:
$103.77
24h Volume:
6.17M
Relative Volume:
0.62
Market Cap:
$174.89B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
32.67
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
-1.13%
1M Performance:
-13.37%
6M Performance:
-2.87%
1Y Performance:
-24.51%
1-Day Range:
$101.02
$104.22
1-Week Range:
$101.02
$104.54
52-Week Range:
$81.97
$135.45
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
101.07 | 179.08B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.51 | 114.23B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
269.75 | 104.87B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.68 | 64.66B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.73 | 50.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott to pay nearly $385 million to settle infant formula allegations - ConsumerAffairs
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery - Yahoo Finance Singapore
Abbott Laboratories stock reports Q2 growth and earnings beat - AD HOC NEWS
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Abbott Laboratories stock rises 0.69 percent ahead of the open - AD HOC NEWS
Abbott partners with Berry Street to add nutrition coaching to Lingo - Drug Delivery Business
Abbott Laboratories stock ends the day 0.69 percent higher at USD 103.69 - AD HOC NEWS
Abbott Laboratories: A Strong Business At A Fair Price (NYSE:ABT) - Seeking Alpha
Sinocare Asks Court To Rule Device Won't Infringe Abbott IP - Law360
What Makes Abbott Laboratories (ABT) an Attractive Opportunity? - Yahoo Finance
Abbott and Berry Street team up on personalized nutrition tracking - marketscreener.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Abbott and Berry Street partner to combine gluc... - pluang.com
A 15% discount on Abbott's four-week glucose-monitor plans will go to Berry Street users. - stocktitan.net
Abbott Laboratories stock gains 1.12 percent as settlement weighs - AD HOC NEWS
Is Abbott Laboratories (ABT) Still Undervalued On Volt’s First US And Canada Procedures? - simplywall.st
Abbott Laboratories stock heads into the open after a 1.12 percent gain - AD HOC NEWS
The Premium On Abbott Laboratories Keeps Growing. So Does The Case For Stryker and Boston Scientific - trefis.com
Calls to sign infant formula testing bill into law in New York - spectrumlocalnews.com
Abbott Laboratories stock ends the day 1.12 percent higher - AD HOC NEWS
Abbott to pay almost $385M in DOJ settlement over infant formula plant allegations - complianceweek.com
Abbott: Quality Remains, But Exact Sciences Has Raised The Bar For Buy (NYSE:ABT) - Seeking Alpha
Sibionics Challenges Abbott Patent In Glucose Monitor Fight - law360.com
3 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Abbott Laboratories stock gains 0.36 percent as revenue reaches USD 12.6 billion - AD HOC NEWS
Abbott Laboratories stock heads into the open after a 0.7 percent gain - AD HOC NEWS
Abbott vs. Intuitive Surgical: Two Healthcare Titans on Diverging Growth Curves - NAI500
Abbott Laboratories Agencies, 2018 - OpenSecrets
NC gets $216K from Abbott baby formula settlement - Yahoo
NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage - WRAL
Abbott Laboratories stock ends the day modestly higher at the close - AD HOC NEWS
Abbott Laboratories Lobbyists, 2022 - OpenSecrets
Abbott Laboratories Agencies, 2012 - OpenSecrets
Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth - The Motley Fool
Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula - patch.com
Abbott Laboratories stock slips 2.0 percent after Friday close - AD HOC NEWS
Abbott Laboratories Agrees to Pay Over $384 Million to Settle Allegations Related to Contaminated Infant Formula - Sierra Sun Times
Abbott Laboratories stock heads into the open after a 2.0 percent drop. - AD HOC NEWS
Wheels Up for Oslo, With One New Slide: Abbott Paid $385 Million, and Nobody Was Charged - Marler Blog
Abbott Laboratories stock holds near USD 102 after July results - AD HOC NEWS
Why Is the Market Reassessing Abbott Laboratories (ABT)? - Kalkine Media
Abbott Laboratories Lobbyists, 2018 - OpenSecrets
3 Dividend Stocks to Buy and Hold for 10 Years - The Globe and Mail
Abbott's Spine Implants Cause Nerve Damage, Suit Claims - law360.com
Abbott Laboratories to pay $384 million over infant formula contamination risk claims - myvalleynews.com
NYS to receive $9.3 million in Abbott Laboratories baby formula settlement - WGRZ
Abbott Laboratories Stock (ABT) Opinions on Infant Formula Settlement - Quiver Quantitative
Casa Grande baby formula plant tied to $384m settlement over unsafe production - AZPM News
Attorney General James Secures Over $9 Million for New York from Abbott Laboratories for Manufacturing Potentially Unsafe Baby Formula - The Indian Panorama
Why Wall Street Is Becoming Even More Bullish About This Dividend King - The Motley Fool
Abbott settles safety standards federal suit that started in Sturgis - Sturgis Journal
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):